DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline June 10, 2020 • 8:30 AM EDT
Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme June 4, 2020 • 8:00 AM EDT
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2020 American Association for Cancer Research Virtual Annual Meeting II June 1, 2020 • 8:00 AM EDT
DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates May 13, 2020 • 8:00 AM EDT
DelMar Pharmaceuticals [Nasdaq:DMPI] Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors May 5, 2020 • 8:00 AM EDT
DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors March 4, 2020 • 8:30 AM EST
DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors February 19, 2020 • 8:00 AM EST
DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates February 13, 2020 • 8:00 AM EST
DelMar Pharmaceuticals to Attend the 22nd Annual BIO CEO & Investor Conference in New York City February 10 and 11, 2020 February 5, 2020 • 8:00 AM EST